Could signs of Mars life be hidden in its thick layers of clay?
The thick, mineral-rich layers of clay found on Mars suggest that the Red Planet harbored potentially life-hosting environments for long stretches in the ancient past, a new study suggests.
Clays need liquid water to form. These layers are hundreds of feet thick and are thought to have formed roughly 3.7 billion years ago, under warmer and wetter conditions than currently prevail on Mars.
"These areas have a lot of water but not a lot of topographic uplift, so they're very stable," study co-author Rhianna Moore, who conducted the research as a postdoctoral fellow at the University of Texas' Jackson School of Geosciences, said in a statement.
"If you have stable terrain, you're not messing up your potentially habitable environments," Moore added. "Favorable conditions might be able to be sustained for longer periods of time."
On our home planet, such deposits form under specific landscape and climatic conditions.
"On Earth, the places where we tend to see the thickest clay mineral sequences are in humid environments, and those with minimal physical erosion that can strip away newly created weathering products," said co-author Tim Goudge, an assistant professor at the Jackson School's Department of Earth and Planetary Sciences.
However, it remains unclear how Mars' local and global topography, along with its past climate activity, influenced surface weathering and the formation of clay layers.
Using data and images from NASA's Mars Reconnaissance Orbiter — the second-longest-operating spacecraft around Mars, after the agency's 2001 Mars Odyssey — Moore, Goudge, and their colleagues studied 150 clay deposits, looking at their shapes and locations, and how close they are to other features like ancient lakes or rivers.
They found that the clays are mostly located in low areas near ancient lakes, but not close to valleys where water once flowed strongly. This mix of gentle chemical changes and less intense physical erosion helped the clays stay preserved over time.
"[Clay mineral-bearing stratigraphies] tend to occur in areas where chemical weathering was favoured over physical erosion, farther from valley network activity and nearer standing bodies of water," the team wrote in the new study, which was published in the journal Nature Astronomy on June 16.
The findings suggest that intense chemical weathering on Mars may have disrupted the usual balance between weathering and climate.
RELATED STORIES
— NASA's Curiosity Mars rover discovers evidence of ripples from an ancient Red Planet lake (images)
— Ocean's worth of water may be buried within Mars
— We finally know where to look for life on Mars
On Earth, where tectonic activity constantly exposes fresh rock to the atmosphere, carbonate minerals like limestone form when rock reacts with water and carbon dioxide (CO2). This process helps remove CO2 from the air, storing it in solid form and helping regulate the climate over long periods.
On Mars, tectonic activity is non-existent, leading to a lack of carbonate minerals and minimal removal of CO2 from the planet's thin atmosphere. As a result, CO2 released by Martian volcanoes long ago likely stayed in the atmosphere longer, making the planet warmer and wetter in the past — conditions the team believes may have encouraged the clay's formation.
The researchers also speculate that the clay could have absorbed water and trapped chemical byproducts like cations, preventing them from spreading and reacting with the surrounding rock to form carbonates that remain trapped and unable to leech into the surrounding environment.
"[The clay is] probably one of many factors that's contributing to this weird lack of predicted carbonates on Mars," said Moore.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas
Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX) announced its plan to integrate its iLet Bionic Pancreas automated insulin delivery/AID system with Abbott's future dual glucose-ketone sensor in the US. The collaboration aims to enhance real-time decision-making support for individuals with diabetes. The iLet Bionic Pancreas received FDA clearance in May 2023 and is distinguished as the first and only AID system that autonomously makes 100% of insulin dosing decisions. This eliminates the need for carb counting or manual insulin correction calculations for users, though they still need to be 'carb aware.' The system currently supports Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and the new agreement deepens the ongoing partnership between Beta Bionics and Abbott. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The new dual sensor is currently under development and is built on the same form factor as Abbott's FreeStyle Libre 3 Plus and will continuously monitor both glucose and ketone levels. Ketone monitoring is a crucial advancement as it can help detect early signs of diabetic ketoacidosis, which is a serious complication of diabetes. Abbott's dual glucose-ketone sensor has received FDA breakthrough device designation. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products. Beta Bionics Inc. (NASDAQ:BBNX) is a commercial-stage medical device company. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Associated Press
2 hours ago
- Associated Press
CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry
CORAL SPRINGS, FL / ACCESS Newswire / July 4, 2025 / CELFULL, a biotechnology company with over 25 years of expertise in anti-aging science, has announced a major breakthrough in longevity innovation: the global launch of Celfavor® NADH Microcapsules, a patented delivery system that resolves the century-long challenge of NADH instability. Journal papers related to NADH This revolutionary technology-protected by seven international invention patents across the U.S., China, Japan, Canada, and South Korea-delivers unprecedented improvements in stability, bioavailability, and targeted delivery, marking a new era in anti-aging therapeutics known as the 'Microcapsule Age.' To accelerate research across the globe, CELFULL has also launched its Global Research Sharing Program, offering free access to the Celfavor® NADH raw material to scientific institutions worldwide. Celfavor®NADH The only effective NADH - Celfavor ® NADH 'The discovery of the therapeutic effect of stabilized NADH is more important to humankind than the discovery of antibiotics.' noted Nobel Laureate Sir John Eccles, underscoring the importance of this innovation. NADH stands for 'nicotinamide adenine dinucleotide (NAD) + hydrogen (H), often dubbed the 'King of Anti-Aging Molecules,' plays a central role in mitochondrial energy production, antioxidant defense, and the activation of longevity proteins. However, its inherent instability-sensitive to heat, light, oxygen, and stomach acid-has severely limited its clinical applications. Conventional NADH degrades by over 70% in one month at room temperature and must be stored at -20°C, making practical use difficult. 7 patents have been certified CELFULL's research team, led by its AI-powered Multi-Target Anti-Aging Institute, spent over a decade solving this problem. The result: Celfavor® NADH Microcapsules, a proprietary technology featuring 250-350μm microcapsules that protect NADH with a multi-core soluble shell made from food-grade materials. In stability tests simulating harsh conditions (40°C / 75% RH), traditional NADH retained only 3.5% of its activity after six months. By contrast, Celfavor® NADH maintained 98.3% activity-demonstrating over 6x shelf-life extension, even without refrigeration or light shielding. The stability of Celfavor® NADH microspheres The Celfavor® NADH Microcapsule system delivers innovation across four dimensions: 1. Enhanced Stability: Microcapsules shield NADH from air, moisture, light, and stomach acid, preserving its full potency in gastrointestinal conditions for up to 4 hours. 2. Targeted Release: Using AI-optimized wall material, the system enables 'zero release in the stomach and sustained release in the intestine.' Simulated intestinal studies show 24-hour continuous release, extending absorption time by 5-8x. 3. Superior Bioavailability: In human trials, a daily dose of 40mg led to a 98% increase in blood NAD⁺ levels, a 3.2x improvement over regular NADH. Performance also surpassed other NAD⁺ precursors like NMN and NR. 4. Formulation Flexibility: Unlike unstable NADH, Celfavor® NADH can be safely co-formulated with vitamins, coenzymes, or peptides in single or multi-ingredient capsules. Celfavor ® NADH microsphere advanced technology surpasses others Celfavor® NADH Microcapsules have been granted seven invention patents and passed all 12 safety evaluations, including cytotoxicity and long-term toxicity tests. It is currently the only NADH raw material globally to pass full-spectrum safety certification. The only globally certified raw material for toxicology and safety experiments 'We are not just creating better products-we are building a platform for the future of longevity,' said Dr. Juliane Hitzel, CEO of CELFULL. 'With this microcapsule technology, we're launching new delivery systems for vitamins, peptides, and more. And by sharing our raw materials with global researchers, we're fostering a collaborative ecosystem that accelerates anti-aging science.' From solving the NADH stability problem to advancing intelligent delivery systems, CELFULL's innovation signals a major milestone in human longevity science. As the Celfavor® NADH Microcapsule technology rolls out globally, the anti-aging industry enters a new chapter-one defined by precision, efficiency, and collaboration. For business cooperation or research partnerships, please contact: [email protected] | Email: [email protected] Website: SOURCE: CELFULL press release
Yahoo
4 hours ago
- Yahoo
CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry
CORAL SPRINGS, FL / / July 4, 2025 / CELFULL, a biotechnology company with over 25 years of expertise in anti-aging science, has announced a major breakthrough in longevity innovation: the global launch of Celfavor® NADH Microcapsules, a patented delivery system that resolves the century-long challenge of NADH instability. Journal papers related to NADH This revolutionary technology-protected by seven international invention patents across the U.S., China, Japan, Canada, and South Korea-delivers unprecedented improvements in stability, bioavailability, and targeted delivery, marking a new era in anti-aging therapeutics known as the "Microcapsule Age." To accelerate research across the globe, CELFULL has also launched its Global Research Sharing Program, offering free access to the Celfavor® NADH raw material to scientific institutions worldwide. Celfavor®NADH The only effective NADH - Celfavor ® NADH "The discovery of the therapeutic effect of stabilized NADH is more important to humankind than the discovery of antibiotics." noted Nobel Laureate Sir John Eccles, underscoring the importance of this innovation. NADH stands for "nicotinamide adenine dinucleotide (NAD) + hydrogen (H), often dubbed the "King of Anti-Aging Molecules," plays a central role in mitochondrial energy production, antioxidant defense, and the activation of longevity proteins. However, its inherent instability-sensitive to heat, light, oxygen, and stomach acid-has severely limited its clinical applications. Conventional NADH degrades by over 70% in one month at room temperature and must be stored at -20°C, making practical use difficult. 7 patents have been certified CELFULL's research team, led by its AI-powered Multi-Target Anti-Aging Institute, spent over a decade solving this problem. The result: Celfavor® NADH Microcapsules, a proprietary technology featuring 250-350μm microcapsules that protect NADH with a multi-core soluble shell made from food-grade materials. In stability tests simulating harsh conditions (40°C / 75% RH), traditional NADH retained only 3.5% of its activity after six months. By contrast, Celfavor® NADH maintained 98.3% activity-demonstrating over 6x shelf-life extension, even without refrigeration or light shielding. The stability of Celfavor® NADH microspheres The Celfavor® NADH Microcapsule system delivers innovation across four dimensions: 1. Enhanced Stability: Microcapsules shield NADH from air, moisture, light, and stomach acid, preserving its full potency in gastrointestinal conditions for up to 4 hours. 2. Targeted Release: Using AI-optimized wall material, the system enables "zero release in the stomach and sustained release in the intestine." Simulated intestinal studies show 24-hour continuous release, extending absorption time by 5-8x. 3. Superior Bioavailability: In human trials, a daily dose of 40mg led to a 98% increase in blood NAD⁺ levels, a 3.2x improvement over regular NADH. Performance also surpassed other NAD⁺ precursors like NMN and NR. 4. Formulation Flexibility: Unlike unstable NADH, Celfavor® NADH can be safely co-formulated with vitamins, coenzymes, or peptides in single or multi-ingredient capsules. Celfavor ® NADH microsphere advanced technology surpasses others Celfavor® NADH Microcapsules have been granted seven invention patents and passed all 12 safety evaluations, including cytotoxicity and long-term toxicity tests. It is currently the only NADH raw material globally to pass full-spectrum safety certification. The only globally certified raw material for toxicology and safety experiments "We are not just creating better products-we are building a platform for the future of longevity," said Dr. Juliane Hitzel, CEO of CELFULL. "With this microcapsule technology, we're launching new delivery systems for vitamins, peptides, and more. And by sharing our raw materials with global researchers, we're fostering a collaborative ecosystem that accelerates anti-aging science." From solving the NADH stability problem to advancing intelligent delivery systems, CELFULL's innovation signals a major milestone in human longevity science. As the Celfavor® NADH Microcapsule technology rolls out globally, the anti-aging industry enters a new chapter-one defined by precision, efficiency, and collaboration. For business cooperation or research partnerships, please contact:maggie@ | Email: maggie@ SOURCE: CELFULL View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data